We performed a network meta-analysis and cost-effectiveness analysis to evaluate the cost-effectiveness of pembrolizumab and cemiplimab for the treatment of patients with advanced NSCLC with high PD-L1 expression from a societal perspective in the US. This evidence concerns the gene CD274 and non-small cell lung carcinoma.